Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Prospective Study to Evaluate the Specificity of the Cobas TaqScreen MPX Test for Use on the Cobas s 201 System for Screening Plasma Pools From Source Plasma Donors for the Presence of HBV DNA, HCV RNA, and HIV-1 RNA
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-08-23
- Last Posted Date
- 2016-03-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 100000
- Registration Number
- NCT00520273
A Multiple Ascending Dose Study of R1511 in Patients With Type 2 Diabetes Mellitus.
- First Posted Date
- 2007-08-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 41
- Registration Number
- NCT00517465
A Single Ascending Dose Study of R1671 in Patients With Mild Intermittent Asymptomatic Asthma.
- First Posted Date
- 2007-08-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 43
- Registration Number
- NCT00517816
A Dose-Escalating Study of Obinutuzumab in Patients With B-lymphocyte Antigen (CD20+) Malignant Disease (GAUGUIN)
- First Posted Date
- 2007-08-17
- Last Posted Date
- 2016-10-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 134
- Registration Number
- NCT00517530
A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-08-17
- Last Posted Date
- 2016-05-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 17
- Registration Number
- NCT00518011
A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS Plus COPEGUS Compared With PEGASYS Plus COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection.
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-08-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 516
- Registration Number
- NCT00517439
Efficacy, Safety and Tolerability Study of Subcutaneous C.E.R.A. in Pre-Dialysis Participants With Chronic Renal Anemia
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2007-08-17
- Last Posted Date
- 2016-05-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 29
- Registration Number
- NCT00517881
LATINO Study: A Study of Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-08-17
- Last Posted Date
- 2016-04-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 163
- Registration Number
- NCT00517413
A Study of MabThera (Rituximab) in Primary Central Nervous System Lymphoma.
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2007-08-17
- Last Posted Date
- 2014-08-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 5
- Registration Number
- NCT00517699
A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Agents.
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-07-20
- Last Posted Date
- 2014-08-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 36
- Registration Number
- NCT00504777
© Copyright 2024. All Rights Reserved by MedPath